AMPH Q4 2021 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q4 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$121M+26.0% YoY

Gross Profit

$56M46.5% margin

Operating Income

$24M20.1% margin

Net Income

$20M16.3% margin

EPS (Diluted)

$0.39

QoQ Revenue Growth

+7.7%

Cash Flow

Operating Cash Flow

$40M

Free Cash Flow

$34M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$672M

Total Liabilities

$226M

Stockholders' Equity

$446M

Cash & Equivalents

$126M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$121M	$96M	+26.0%
Gross Profit	$56M	$37M	+52.7%
Operating Income	$24M	$3M	+742.4%
Net Income	$20M	-$6M	+415.0%

Revenue Segments

Active Pharmaceutical Ingredient Segment

$6M100%